NO20060483L - VEGF-feller og terapeutiske anvendelser derav - Google Patents

VEGF-feller og terapeutiske anvendelser derav

Info

Publication number
NO20060483L
NO20060483L NO20060483A NO20060483A NO20060483L NO 20060483 L NO20060483 L NO 20060483L NO 20060483 A NO20060483 A NO 20060483A NO 20060483 A NO20060483 A NO 20060483A NO 20060483 L NO20060483 L NO 20060483L
Authority
NO
Norway
Prior art keywords
vegf
therapeutic applications
vegf traps
traps
tissues
Prior art date
Application number
NO20060483A
Other languages
English (en)
Other versions
NO339766B1 (no
Inventor
Thomas J Daly
James P Fandl
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33552268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060483(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NO20060483L publication Critical patent/NO20060483L/no
Publication of NO339766B1 publication Critical patent/NO339766B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Nukleinsyremolekyler og multimeriske proteiner som er i stand til å binde vaskulær endotelial vekstfaktor (VEGF). VEGF-feller som er terapeutisk nyttige til behandling av VEGF-assosierte tilstander og sykdommer og som er spesielt tilpasset lokal administrasjon til spesifikke organer, vev og/eller celler, blir fremlagt.
NO20060483A 2003-06-30 2006-01-30 VEGF-feller og terapeutiske anvendelser derav NO339766B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/609,775 US7087411B2 (en) 1999-06-08 2003-06-30 Fusion protein capable of binding VEGF
PCT/US2004/021059 WO2005000895A2 (en) 2003-06-30 2004-06-29 Vegf traps and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
NO20060483L true NO20060483L (no) 2006-03-28
NO339766B1 NO339766B1 (no) 2017-01-30

Family

ID=33552268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060483A NO339766B1 (no) 2003-06-30 2006-01-30 VEGF-feller og terapeutiske anvendelser derav

Country Status (29)

Country Link
US (4) US7087411B2 (no)
EP (2) EP1639007B1 (no)
JP (2) JP2007528708A (no)
KR (1) KR101131429B1 (no)
CN (1) CN1816566B (no)
AR (1) AR044938A1 (no)
AT (2) ATE427962T1 (no)
AU (1) AU2004252175B2 (no)
BR (1) BRPI0412125A (no)
CA (1) CA2529660C (no)
CY (2) CY1109204T1 (no)
DE (2) DE602004020474D1 (no)
DK (2) DK1947118T3 (no)
ES (2) ES2323468T3 (no)
HK (1) HK1082511A1 (no)
IL (2) IL172404A (no)
MX (1) MXPA05013641A (no)
MY (1) MY154826A (no)
NO (1) NO339766B1 (no)
NZ (2) NZ572107A (no)
PL (2) PL1947118T3 (no)
PT (2) PT1639007E (no)
RU (1) RU2376373C2 (no)
SI (2) SI1947118T1 (no)
TW (1) TWI330197B (no)
UA (2) UA105625C2 (no)
UY (1) UY28396A1 (no)
WO (1) WO2005000895A2 (no)
ZA (1) ZA200600157B (no)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
EP3195874A1 (en) 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
WO2007022101A2 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
WO2007041614A2 (en) * 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use
PT1962895E (pt) * 2005-12-16 2013-03-28 Regeneron Pharma Utilização terapêutica de um antagonista dll4 e de um inibidor fcev para inibição de crescimento de tumores
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
KR101406811B1 (ko) * 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
MX2009013004A (es) 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP2358746B1 (en) * 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
EP2350264A4 (en) * 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATORY RESPIRATORY DISEASES
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES
WO2010127029A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011146902A1 (en) 2010-05-21 2011-11-24 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5826270B2 (ja) 2010-07-28 2015-12-02 グリックニック インコーポレイテッド 規則的に多量体化された免疫グロブリンＦｃ組成物を作製するための天然ヒトタンパク質断片の融合タンパク質
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9441029B2 (en) 2010-08-06 2016-09-13 Genzyme Corporation VEGF antagonist compositions and uses thereof
WO2012064792A2 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
CN103874709B (zh) 2011-08-19 2016-12-21 瑞泽恩制药公司 抗tie2抗体及其用途
IN2014CN03042A (no) 2011-09-30 2015-07-03 Regeneron Pharma
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
ES2775104T5 (es) 2011-11-18 2023-06-08 Regeneron Pharma Método de fabricación de una formulación farmacéutica de liberación prolongada que comprende micropartículas de proteínas recubiertas de polímero utilizando secado por pulverización
CN104159926B (zh) * 2011-12-01 2019-02-01 圆祥生命科技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
SG10201709018QA (en) 2012-03-14 2017-11-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015010691A2 (pt) 2012-11-13 2017-08-22 Regeneron Pharma Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
EP2970448B1 (en) 2013-03-14 2021-11-03 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN110193009A (zh) 2013-07-12 2019-09-03 伊维希比奥公司 用于治疗或预防眼科病的方法
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
WO2015058369A1 (en) * 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EA035809B1 (ru) 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
TW202336236A (zh) 2015-03-27 2023-09-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
BR112017022417B1 (pt) * 2015-04-23 2022-07-19 Hemanext Inc Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para reduzir a saturação de oxigênio do sangue durante o armazenamento
MA56416A (fr) 2015-05-12 2022-05-04 Regeneron Pharma Détermination de la pureté de protéines multimériques
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3353212B1 (en) 2015-09-23 2021-11-03 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof
WO2017058923A1 (en) 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017070866A1 (zh) * 2015-10-28 2017-05-04 黄志清 一种抗血管内皮生长因子的氧化石墨烯与其用途
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR102261636B1 (ko) 2015-12-03 2021-06-07 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2016369557B2 (en) 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
PT3394103T (pt) 2015-12-22 2023-09-04 Regeneron Pharma Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN114478801A (zh) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
AU2017257169B2 (en) 2016-04-29 2021-07-08 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
EP4344748A2 (en) 2016-06-10 2024-04-03 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
CN117593361A (zh) 2016-07-29 2024-02-23 里珍纳龙药品有限公司 具有集成电子视觉检查的组装线
AU2017312785A1 (en) 2016-08-16 2019-01-24 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
IL264640B2 (en) 2016-08-18 2024-03-01 Regeneron Pharma An assay to determine protein self-association potential using concentration-dependent self-interaction nanoparticle spectroscopy
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EA201990781A9 (ru) 2016-09-23 2019-11-27 Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
DK3515487T3 (da) 2016-09-23 2023-08-28 Regeneron Pharma Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
TW202237071A (zh) 2016-10-07 2022-10-01 美商再生元醫藥公司 於室溫穩定之冷凍乾燥蛋白質
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
KR20230119729A (ko) 2016-10-25 2023-08-16 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, MULTIMERIZING STRADOMER
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
AU2018225102A1 (en) 2017-02-21 2019-09-05 Regeneron Pharmaceuticals, Inc. Anti-PD-1 antibodies for treatment of lung cancer
AU2018234918B2 (en) 2017-03-17 2023-11-02 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
IL270267B1 (en) 2017-05-06 2024-02-01 Regeneron Pharma Methods for treating eye disorders with APLNR antagonists and VEGF inhibitors
EA202090149A1 (ru) 2017-06-28 2020-05-31 Ридженерон Фармасьютикалз, Инк. Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
MX2020000228A (es) 2017-07-06 2020-08-10 Regeneron Pharma Proceso de cultivo celular para producir una glicoproteina.
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CA3078974A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
CN111465848B (zh) 2017-12-13 2023-11-28 里珍纳龙药品有限公司 管理层析柱床支架的装置和系统及相关方法
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
AU2019212622A1 (en) 2018-01-26 2020-08-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TWI825066B (zh) 2018-02-01 2023-12-11 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
TW202323813A (zh) 2018-03-19 2023-06-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
WO2019197676A1 (en) 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
WO2019212965A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202005985A (zh) 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
BR112021002432A2 (pt) 2018-08-13 2021-05-04 Regeneron Pharmaceuticals, Inc. seleção de proteína terapêutica em condições in vivo simuladas
EP3775926A1 (en) 2018-08-30 2021-02-17 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
EA202191107A1 (ru) 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
WO2020150492A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
KR20210120042A (ko) 2019-01-25 2021-10-06 리제너론 파아마슈티컬스, 인크. 공제형에서 이량체의 정량화 및 식별
JP2022517821A (ja) 2019-01-25 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド プロテインａクロマトグラフィー－エレクトロスプレーイオン化質量分析計
US20220153819A1 (en) 2019-02-12 2022-05-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
EP3927435A1 (en) 2019-02-21 2021-12-29 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
CA3129963A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
JP2022528807A (ja) 2019-04-17 2022-06-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 宿主細胞タンパク質の同定
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
CN113785203A (zh) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
MA55965A (fr) 2019-05-13 2022-03-23 Regeneron Pharma Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
US20200399371A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
AU2020296181A1 (en) 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
EP4034870A1 (en) 2019-09-24 2022-08-03 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
WO2021113591A1 (en) * 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
KR102519234B1 (ko) 2019-12-06 2023-04-10 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
BR122023021668A2 (pt) 2020-01-21 2024-01-09 Regeneron Pharmaceuticals, Inc. Método para determinar a estabilidade de uma proteína de interesse
US20230060095A1 (en) 2020-01-24 2023-02-23 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
EP4111206A1 (en) 2020-02-27 2023-01-04 Regeneron Pharmaceuticals, Inc. Methods of reducing polysorbate degradation in drug formulations
EP4110472A1 (en) 2020-02-28 2023-01-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
WO2021178814A1 (en) 2020-03-06 2021-09-10 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
WO2021202554A1 (en) 2020-03-30 2021-10-07 Regeneron Pharmaceuticals, Inc. Methods for characterizing low-abundance host cell proteins
CN115803009A (zh) * 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
JP2023530187A (ja) 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
CN115776890A (zh) 2020-07-16 2023-03-10 拉夸里亚创药株式会社 作为眼病治疗剂的trpv4抑制剂
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
WO2022072762A1 (en) 2020-10-02 2022-04-07 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
CN116406379A (zh) 2020-10-22 2023-07-07 瑞泽恩制药公司 抗fgfr2抗体和其使用方法
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
JP2023551446A (ja) 2020-11-25 2023-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水膜乳化を使用した持続放出製剤
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
KR20230134117A (ko) 2021-01-20 2023-09-20 리제너론 파마슈티칼스 인코포레이티드 세포 배양물에서 단백질 역가를 개선시키는 방법
WO2022159875A1 (en) 2021-01-25 2022-07-28 Regeneron Pharmaceuticals, Inc. Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)
US20240034796A1 (en) 2021-02-04 2024-02-01 Genuv Inc. Anti-pd-1 antibody and use thereof
WO2022173931A1 (en) 2021-02-11 2022-08-18 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
CA3170733A1 (en) 2021-02-23 2022-09-01 Petra RIETSCHEL Methods of treating lung cancer by administering a pd-1 inhibitor
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
JP2024511106A (ja) 2021-03-23 2024-03-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法
WO2022204728A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
WO2022247917A1 (zh) 2021-05-28 2022-12-01 上海瑞宏迪医药有限公司 衣壳变异的重组腺相关病毒及其应用
IL308864A (en) 2021-06-01 2024-01-01 Regeneron Pharma In-house capillary electrophoresis tests and reagents
IL309048A (en) 2021-06-22 2024-02-01 Regeneron Pharma Anti-EGFRVIII drug antibody conjugates and uses thereof
US20230045769A1 (en) 2021-07-13 2023-02-09 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based strategy for determining product-related variants of a biologic
US20230018713A1 (en) 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CA3230317A1 (en) 2021-09-14 2023-03-23 Regeneron Pharmaceuticals, Inc. Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic
IL310957A (en) 2021-09-28 2024-04-01 Regeneron Pharma Tests for quantifying drugs and target concentrations
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023076612A1 (en) 2021-11-01 2023-05-04 Regeneron Pharmaceuticals, Inc. Methods to prevent disulfide scrambling for ms-based proteomics
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230235089A1 (en) 2021-11-24 2023-07-27 Regeneron Pharmaceuticals, Inc. Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies
AR127806A1 (es) 2021-12-01 2024-02-28 Kadmon Corp Llc Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15
WO2023137026A1 (en) 2022-01-12 2023-07-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
AU2650597A (en) * 1996-05-02 1997-11-26 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivatives
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
CA2330527A1 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
MEP3208A (xx) * 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF

Also Published As

Publication number Publication date
ES2323468T3 (es) 2009-07-16
IL172404A0 (en) 2006-04-10
MY154826A (en) 2015-07-31
NO339766B1 (no) 2017-01-30
US20050043236A1 (en) 2005-02-24
PT1947118E (pt) 2010-12-02
WO2005000895A3 (en) 2005-09-15
JP2010246557A (ja) 2010-11-04
UA90657C2 (ru) 2010-05-25
CY1111605T1 (el) 2015-10-07
CA2529660C (en) 2013-08-06
SI1639007T1 (sl) 2009-08-31
CA2529660A1 (en) 2005-01-06
NZ572107A (en) 2009-01-31
AR044938A1 (es) 2005-10-12
RU2006102497A (ru) 2006-06-10
TWI330197B (en) 2010-09-11
CN1816566A (zh) 2006-08-09
MXPA05013641A (es) 2006-02-24
US7972598B2 (en) 2011-07-05
EP1947118A1 (en) 2008-07-23
US20090062200A1 (en) 2009-03-05
AU2004252175B2 (en) 2010-07-22
UY28396A1 (es) 2004-11-08
ES2354847T3 (es) 2011-03-18
ATE486091T1 (de) 2010-11-15
EP1639007B1 (en) 2009-04-08
US20100087632A1 (en) 2010-04-08
SI1947118T1 (sl) 2011-02-28
IL204984A (en) 2011-12-29
ATE427962T1 (de) 2009-04-15
US20040014667A1 (en) 2004-01-22
KR101131429B1 (ko) 2012-07-27
IL172404A (en) 2011-12-29
BRPI0412125A (pt) 2006-08-15
DK1639007T3 (da) 2009-06-08
DE602004029833D1 (de) 2010-12-09
KR20060096184A (ko) 2006-09-08
TW200513532A (en) 2005-04-16
CY1109204T1 (el) 2014-07-02
US7279159B2 (en) 2007-10-09
PL1639007T3 (pl) 2009-11-30
UA105625C2 (uk) 2014-06-10
PT1639007E (pt) 2009-06-04
ZA200600157B (en) 2007-04-25
EP1947118B1 (en) 2010-10-27
HK1082511A1 (en) 2006-06-09
WO2005000895A2 (en) 2005-01-06
JP2007528708A (ja) 2007-10-18
AU2004252175A1 (en) 2005-01-06
PL1947118T3 (pl) 2011-05-31
NZ544569A (en) 2008-12-24
CN1816566B (zh) 2011-01-12
RU2376373C2 (ru) 2009-12-20
US7635474B2 (en) 2009-12-22
EP1639007A2 (en) 2006-03-29
DE602004020474D1 (de) 2009-05-20
DK1947118T3 (da) 2011-02-07
US7087411B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
NO20060483L (no) VEGF-feller og terapeutiske anvendelser derav
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
NO20054769L (no) Substituerte fenylalkansyrer
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20064388L (no) Kaseinavledede peptider og terapeutiske anvendelser derav
AU2002305450A1 (en) Proteomimetic compounds and methods
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
NO20063926L (no) N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse
NO20045076L (no) Fremgangsmate og apparatur for ultralydbehandling av bindevev
PT1200105E (pt) Factor viii modificado
DE602005011943D1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
WO2007038686A3 (en) Amniotic membrane preparations and purified compositions and methods of use
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
DE112008001019A5 (de) Biologisch wirksame Moleküle, insbesondere auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2005051902A3 (en) Modified mscl protein channel
ATE509957T1 (de) An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
WO2012066581A9 (en) Novel conjugates for targeted drug delivery